Resource impact statement
No significant resource impact is anticipated
NICE has recommended pembrolizumab as an option for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older. It is recommended if they have had an autologous stem cell transplant that has not worked or they have had at least 2 previous therapies and an autologous stem cell transplant is not an option, and only if they have not had brentuximab vedotin and the company provides pembrolizumab according to the commercial arrangement (see section 2 of guidance).
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option and the overall cost of treatment will be similar.
Pembrolizumab and the other treatment options in the pathway (nivolumab, and brentuximab vedotin) have discounts that are commercial in confidence. For enquiries about the patient access schemes contact the manufacturers.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: